Colorado State University Research Foundation

University of California

The Brigham and Women's Hospital, Inc.

Microbial Chemistry Research Foundation

Patrick Joseph Brennan

Michael B Brenner

Masayuki Igarashi

Steven A Porcelli

Robert L Modlin

Dean Calvin Crick

Yoshimasa Ishizaki

Peter A Sieling

A drug combination against acid-fast bacillus, including: an inhibitor for WecA or an ortholog thereof; and at least one of an inhibitor for MurX or an ortholog thereof and an RNA synthesis inhibitor, wherein the inhibitor for WecA or an ortholog thereof is used in combination with the at least one of an inhibitor for MurX or an ortholog thereof and an RNA synthesis inhibitor; a screening method for a drug against acid-fast bacillus; and an inhibitor for WecA or an ortholog thereof.

Combined anti-acid-fast bacterial agent, screening method for anti-acid-fast bacterial agents, and activity inhibitor of WecA or ortholog thereof

The present invention is based on the observation that CD1 functions to present foreign and autoimmune antigens to a select subpopulation of T-cells. Based on this observation, the present invention provides methods for detecting the presence of a CD1-presented antigen in a sample, methods for purifying CD1-presented antigens, vaccines containing CD1-presented antigens, methods of blocking CD1 antigen presentation, methods of identifying and/or isolating CD1 blocking agents, methods of inducing CD1 expression, and T-cell lines for use in the methods disclosed herein. The CD1-presented antigens of the invention, unlike MHC-presented antigens, are non-polypeptide hydrophobic antigens. In particular, a CD1-presented antigen isolated from several mycobacterial species is a lipoarabinomannan (LAM).

Method for inducing a CD1-restricted immune response

Growing community of inventors

Fort Collins, CO, United States of America

Patrick Joseph Brennan